Diligence memo · auto-generated · as of July 2, 2026

Vitality Biopharma, Inc.

Vitality Biopharma, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Vitality Biopharma, Inc. operates in Pharmaceuticals, based in LOS ANGELES.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Vitality Biopharma, Inc. has raised $39M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $36M on 2018-10-22.

Most recent recorded round closed around 2018-10-22.

Valuation (modeled)modeled

Provath models Vitality Biopharma, Inc. at approximately $1.2B (range $76M–$4.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.80× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 24 months.

Last raise 7.7 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 24.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 78% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 91% of those peers.

Closest niche peers: LP Investors, LLC, GigaGen, Inc., Madrigal Pharmaceuticals, Inc., Slayback Pharma Ltd Liability Co, X4 Pharmaceuticals, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.